Iridex (IRIX) Q2 2026 earnings review
Retina Weakness Halts Revenue Growth, Pressuring the Turnaround Story
Iridex's turnaround narrative hit a roadblock in Q2, with total revenue reversing to a 7% YoY decline ($12.6M) after a string of consecutive growth quarters. The culprit is the Retina segment, which fell sharply due to macro disruptions in the Middle East and China. While the Glaucoma (Cyclo G6) segment is accelerating rapidly (+19% revenue), it could not offset the broader decline. Crucially, Adjusted EBITDA flipped back to negative (-$0.4M) after management had previously declared their financial transformation successful. Reaffirming full-year revenue guidance of $51-$53M implies a steep and risky operational ramp is required in the second half of the year.
🐂 Bull Case
Probe volumes accelerated by 35% YoY to 17,700 units, driving a 19% increase in segment revenue. The strategy to drive higher utilization within the existing installed base is yielding clear results.
Operating expenses decreased by 5% YoY to $5.3M. The ongoing relocation of G&A functions and the transition to lower-cost contract manufacturers are actively protecting the bottom line.
🐻 Bear Case
Flagship Retina sales decelerated drastically, dropping to $6.5M from $8.0M a year ago. Management blames macro issues, but the magnitude of the drop threatens the entire year's growth profile.
After touting a return to positive Adjusted EBITDA in recent quarters, the metric reversed to a $353k loss this quarter, highlighting the fragility of Iridex's margin structure.
⚖️ Verdict: 🔴
Bearish. The growth engine stalled due to external macro factors, and the return to negative Adjusted EBITDA undermines management's recent victory laps regarding sustained profitability. H2 execution risk is exceptionally high.
Key Themes
Glaucoma Probe Utilization Surges
Accelerating. The Cyclo G6 product family is the undeniable bright spot. Probe sales volume surged 35% YoY (17,700 vs 13,100), generating $3.9M in segment revenue (+19% YoY). This proves the commercial team's strategy to leverage the MedScout platform to drive recurring, high-margin disposable utilization among existing users is working.
Retina Segment Headwinds Persist
Reversing. Retina product revenue fell sharply to $6.5M from $8.0M in the prior year. While the U.S. market holds up, the segment is being dragged down by two major macro factors: geopolitical disruptions impacting the Middle East (previously 5% of total revenue) and reduced sell-through in China. Management expects relief as international regulatory approvals for the PASCAL platform advance, but timing remains uncertain.
Profitability Narrative Stumbles
Reversing. Over the past year, management aggressively promoted their 'successful business transformation' and sustained positive Adjusted EBITDA. Q2 contradicts this narrative. Adjusted EBITDA reverted to a loss of $353k (down from +$21k YoY and +$259k in Q1). Gross margins remain compressed at 34.2%, failing to show the operating leverage investors were promised.
Aggressive OpEx Management
Stable. The company continues to squeeze costs out of the organization. Total operating expenses fell 5% YoY to $5.3M, primarily due to lower G&A expenses stemming from the ongoing transfer of administrative functions out of California. This discipline is the only factor preventing steeper bottom-line losses.
Strategic Inventory Build for Relocation
Accelerating. Management announced they will use more working capital to intentionally build inventory. This is a defensive driver designed to secure international supply chains and protect distributor revenue streams against potential interruptions as the company physically relocates its headquarters and transitions to contract manufacturers later this year.
Cash Runway is Tightening
Decelerating. Total cash and cash equivalents sit at just $4.7M. While operating cash flow was reportedly positive in Q2, the planned use of working capital to stockpile inventory ahead of the headquarters move puts immense pressure on a balance sheet with very little margin for error.
MicroPulse and PASCAL as Core Technological Pillars
Stable. The company's future remains intrinsically tied to its proprietary MicroPulse technology (minimizing tissue damage in Glaucoma) and the PASCAL laser platform for Retina. Securing MDR and international regulatory approvals for these specific platforms is the primary gateway to resuming international growth.
Other KPIs
Stable YoY, but fundamentally depressed. This is a slight decrease from 34.5% a year ago and a sequential drop from 40.2% in Q1. Meaningful gross margin improvement relies entirely on the successful transition to third-party contract manufacturers, which will take time to reflect in the P&L.
Decelerating. A 5% decrease from $5.62M in Q2 2025. This reflects the realization of savings from the administrative function transfer initiative. Management continues to execute well on variables within their direct control.
Guidance
Accelerating (Implied). Management reaffirmed this guidance. However, with H1 2026 revenue at only $24.4M, the company must generate roughly $27.6M in H2 (an average of $13.8M per quarter) to hit the midpoint. This requires a significant and immediate acceleration from Q2's $12.6M run rate.
Stable. Reaffirmed guidance. With H1 adjusted OpEx tracking in line with expectations, this target appears highly achievable and underscores management's commitment to cost containment during top-line turbulence.
Key Questions
Bridging the H2 Revenue Gap
With H1 revenue at $24.4M, hitting the $52M midpoint requires a massive H2 step-up. Given the persistent macro headwinds in Retina, exactly what specific product lines or regions are expected to drive this $27.6M H2 requirement?
Working Capital and Cash Runway
You ended Q2 with $4.7M in cash and plan to draw down working capital to build inventory ahead of the HQ move. What is the minimum cash balance you are comfortable operating with, and is there a risk of needing to raise capital before year-end?
EBITDA Reversal
After declaring the financial transformation complete and achieving positive Adjusted EBITDA in recent quarters, Q2 fell back to a loss. Was this purely a function of the top-line Retina miss, or were there unexpected costs associated with the manufacturing transition?
International Regulatory Approvals
You cited advancing international regulatory approvals for PASCAL as a catalyst for Retina recovery. What specific geographies and approval milestones are slated for H2 2026?